These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 14280300)

  • 1. ADRENOCORTICAL CARCINOMA TREATED WITH O,P' -DDD.
    MONTGOMERY DA; WELBOURN RB
    Br Med J; 1965 May; 1(5446):1356-8. PubMed ID: 14280300
    [No Abstract]   [Full Text] [Related]  

  • 2. AN EFFECT OF O,P'-DDD ON THE EXTRA-ADRENAL METABOLISM OF CORTISOL IN MAN.
    BLEDSOE T; ISLAND DP; NEY RL; LIDDLE GW
    J Clin Endocrinol Metab; 1964 Dec; 24():1303-11. PubMed ID: 14243174
    [No Abstract]   [Full Text] [Related]  

  • 3. TREATMENT OF ADRENOCORTICAL CANCER WITH O,P'-DDD.
    NETTO AD; WAJCHENBERG BL; RAVAGLIA C; PEREIRA VG; SHNAIDER J; PUPO AA; CINTRA AB
    Ann Intern Med; 1963 Jul; 59():74-8. PubMed ID: 14042612
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapy of adrenocortical cancer with o,p' DDD in two children.
    FISHER DA; PANOS TC; MELBY JC
    J Clin Endocrinol Metab; 1963 Feb; 23():218-21. PubMed ID: 24546774
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of o,p'-DDD therapy on plasma cholesterol in adrenal carcinoma.
    MOLNAR GD; NUNN SL; TAUXE WN
    Proc Staff Meet Mayo Clin; 1961 Nov; 36():618-20. PubMed ID: 14475247
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical and therapeutic observations in the adrenal cancer: a report on 7 patients treated with o,p'-DDD.
    MOLNAR GD; MATTOX VR; BAHN RC
    Cancer; 1963 Feb; 16():259-68. PubMed ID: 13935915
    [No Abstract]   [Full Text] [Related]  

  • 7. o,p'-DDD (mitotane) treatment for Cushing's syndrome: adrenal drug concentration and inhibition in vitro of steroid synthesis.
    Touitou Y; Moolenaar AJ; Bogdan A; Auzéby A; Luton JP
    Eur J Clin Pharmacol; 1985; 29(4):483-7. PubMed ID: 4092727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of adrenocortical cancer treated with O,P'-DDD.
    Sakauchi N; Kumaoka S; Naruke T; Abe O; Kusama M
    Endocrinol Jpn; 1969 Apr; 16(2):287-90. PubMed ID: 5819718
    [No Abstract]   [Full Text] [Related]  

  • 9. Significant regression of the tumor combined with the high level of plasma cortisol by low-dose administration of O, p'-DDD in a case with Cushing's syndrome caused by adrenocortical carcinoma.
    Otokida K; Nakamura M; Takeda M; Ito T; Kato M; Masuda T; Tashiro A
    Tohoku J Exp Med; 1986 Dec; 150(4):407-15. PubMed ID: 3564003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remission in Cushing's syndrome with o,p'-DDD.
    Southren AL; Tochimoto S; Strom L; Ratuschni A; Ross H; Gordon G
    J Clin Endocrinol Metab; 1966 Mar; 26(3):268-78. PubMed ID: 4286017
    [No Abstract]   [Full Text] [Related]  

  • 11. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.
    Kroiss M; Plonné D; Kendl S; Schirmer D; Ronchi CL; Schirbel A; Zink M; Lapa C; Klinker H; Fassnacht M; Heinz W; Sbiera S
    Eur J Endocrinol; 2016 Mar; 174(3):343-53. PubMed ID: 26671975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
    Cerquetti L; Bucci B; Marchese R; Misiti S; De Paula U; Miceli R; Muleti A; Amendola D; Piergrossi P; Brunetti E; Toscano V; Stigliano A
    Endocr Relat Cancer; 2008 Jun; 15(2):623-34. PubMed ID: 18509009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma level monitoring of mitotane (o,p'-DDD) and its metabolite (o,p'-DDE) during long-term treatment of Cushing's disease with low doses.
    Benecke R; Keller E; Vetter B; de Zeeuw RA
    Eur J Clin Pharmacol; 1991; 41(3):259-61. PubMed ID: 1748144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of chlodithane (o,p'-DDD) on transcortin binding ability in Itsenko-Cushing's disease].
    Tron'ko MD
    Fiziol Zh; 1970; 16(6):844-5. PubMed ID: 5520073
    [No Abstract]   [Full Text] [Related]  

  • 15. [Multiple recurrence of Cushing's syndrome after bilateral adrenalectomy and pituitary gland surgery. Cure with o,p'-DDD].
    Bigler U; Müller J
    Schweiz Med Wochenschr; 1978 Jan; 108(2):67-72. PubMed ID: 622536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACTH-like excretion from carcinoma of the ovary. The clinical effect of m,p'-DDD.
    NICHOLS J; WARREN JC; MANTZ FA
    JAMA; 1962 Nov; 182():713-8. PubMed ID: 13938342
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro.
    Theile D; Haefeli WE; Weiss J
    Endocrine; 2015 Aug; 49(3):842-53. PubMed ID: 25542188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?
    Dickstein G; Shechner C; Arad E; Best LA; Nativ O
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3100-3. PubMed ID: 9745410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid micromethod for the analysis of mitotane and its metabolite in plasma by gas chromatography with electron-capture detection.
    Benecke R; Vetter B; De Zeeuw RA
    J Chromatogr; 1987 Jul; 417(2):287-94. PubMed ID: 3654882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-dimensional chromatography for enantiomeric analysis of mitotane and its metabolite o,p'-DDA in patients with adrenocortical carcinoma indicates enantioselective metabolism.
    Stadler G; de Almeida Veiga A; Rita Corso C; Bach de Assis C; de Toledo Nogueira B; Regina Rocha Martins L; Cruz Bonk B; Lada Degaut Pontes F; Cavalcante de Figueiredo B; Mera de Souza L
    Bioorg Chem; 2023 Dec; 141():106835. PubMed ID: 37713949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.